Notice: This company has been marked as potentially delisted and may not be actively trading. ContraVir Pharmaceuticals (CTRV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CTRV vs. TRVN, ONCT, ATNF, ASLN, CWBR, ADXS, EVFM, CYTO, BPTSY, and UPCShould you be buying ContraVir Pharmaceuticals stock or one of its competitors? The main competitors of ContraVir Pharmaceuticals include Trevena (TRVN), Oncternal Therapeutics (ONCT), 180 Life Sciences (ATNF), ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Ayala Pharmaceuticals (ADXS), Evofem Biosciences (EVFM), Altamira Therapeutics (CYTO), Biophytis (BPTSY), and Universe Pharmaceuticals (UPC). These companies are all part of the "medical" sector. ContraVir Pharmaceuticals vs. Trevena Oncternal Therapeutics 180 Life Sciences ASLAN Pharmaceuticals CohBar Ayala Pharmaceuticals Evofem Biosciences Altamira Therapeutics Biophytis Universe Pharmaceuticals ContraVir Pharmaceuticals (NASDAQ:CTRV) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Which has better earnings and valuation, CTRV or TRVN? ContraVir Pharmaceuticals has higher earnings, but lower revenue than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContraVir PharmaceuticalsN/AN/A-$9.45MN/AN/ATrevena$3.12M0.50-$40.29M-$47.04-0.04 Does the media prefer CTRV or TRVN? In the previous week, Trevena had 1 more articles in the media than ContraVir Pharmaceuticals. MarketBeat recorded 1 mentions for Trevena and 0 mentions for ContraVir Pharmaceuticals. ContraVir Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score. Company Overall Sentiment ContraVir Pharmaceuticals Neutral Trevena Neutral Do insiders and institutionals hold more shares of CTRV or TRVN? 1.1% of ContraVir Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 1.6% of ContraVir Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend CTRV or TRVN? Trevena has a consensus target price of $5.00, indicating a potential upside of 173.22%. Given Trevena's stronger consensus rating and higher possible upside, analysts clearly believe Trevena is more favorable than ContraVir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ContraVir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor CTRV or TRVN? Trevena received 397 more outperform votes than ContraVir Pharmaceuticals when rated by MarketBeat users. However, 74.49% of users gave ContraVir Pharmaceuticals an outperform vote while only 69.45% of users gave Trevena an outperform vote. CompanyUnderperformOutperformContraVir PharmaceuticalsOutperform Votes21974.49% Underperform Votes7525.51% TrevenaOutperform Votes61669.45% Underperform Votes27130.55% Is CTRV or TRVN more profitable? Trevena's return on equity of 0.00% beat ContraVir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ContraVir PharmaceuticalsN/A -4,810.77% -130.14% Trevena N/A N/A -119.55% Which has more risk and volatility, CTRV or TRVN? ContraVir Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Trevena has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. SummaryTrevena beats ContraVir Pharmaceuticals on 9 of the 12 factors compared between the two stocks. Get ContraVir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTRV vs. The Competition Export to ExcelMetricContraVir PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$375,000.00$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A10.0188.8317.53Price / SalesN/A337.621,282.53134.37Price / CashN/A22.6336.6032.90Price / Book0.595.084.964.69Net Income-$9.45M$154.90M$117.89M$224.57M ContraVir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTRVContraVir PharmaceuticalsN/A$0.32-31.4%N/A-78.0%$257,000.00N/A0.0014Gap DownHigh Trading VolumeTRVNTrevena0.9555 of 5 stars$1.84+1.1%$5.00+171.7%-89.5%$1.59M$443,000.00-0.0440Analyst ForecastONCTOncternal Therapeutics1.3858 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530Analyst ForecastNews CoverageATNF180 Life SciencesN/A$1.49-1.3%N/A-61.0%$1.53MN/A0.007News CoveragePositive NewsGap UpASLNASLAN PharmaceuticalsN/A$0.60flat$76.00+12,566.7%N/A$1.23M$12M-0.0330CWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010ADXSAyala PharmaceuticalsN/A$0.03-10.0%N/A-95.6%$1.15M$3.24M0.0020Analyst ForecastNews CoverageGap UpHigh Trading VolumeEVFMEvofem Biosciences0.5801 of 5 stars$0.01-3.1%N/A-75.0%$1.08M$11.39M-0.02120CYTOAltamira TherapeuticsN/A$0.30-25.9%N/A-86.5%$1.02M$320,000.000.0020Gap UpHigh Trading VolumeBPTSYBiophytisN/A$2.81-6.1%N/AN/A$986,000.00N/A0.0022News CoverageGap DownUPCUniverse PharmaceuticalsN/A$0.52-17.4%N/A-98.5%$892,000.00$26.73M0.00220 Related Companies and Tools Related Companies Trevena Competitors Oncternal Therapeutics Competitors 180 Life Sciences Competitors ASLAN Pharmaceuticals Competitors CohBar Competitors Ayala Pharmaceuticals Competitors Evofem Biosciences Competitors Altamira Therapeutics Competitors Biophytis Competitors Universe Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTRV) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraVir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTRV Stock Alerts